The US Food and Drug Administration (FDA) has sent a warning letter to Laboratoires Clarins following an inspection of its drug manufacturing facility at 5 rue Ampére, Pontoise, France, conducted in September 2018. In its letter, FDA summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See 21 CFR, parts 210 and 211. FDA stated “Because your methods, facilities, or controls for manufacturing, processing, packing, or holding d...